202 related articles for article (PubMed ID: 29121363)
1. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
3. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
5. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
6. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
8. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
[No Abstract] [Full Text] [Related]
9. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
10. Vogt-Koyanagi-Harada disease presenting as optic neuritis.
Rajendram R; Evans M; Khurana RN; Tsai JH; Rao NA
Int Ophthalmol; 2007; 27(2-3):217-20. PubMed ID: 17437062
[TBL] [Abstract][Full Text] [Related]
11. Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.
Apivatthakakul A; Kunavisarut P; Rothova A; Pathanapitoon K
Ocul Immunol Inflamm; 2020 Apr; 28(3):505-508. PubMed ID: 31161956
[No Abstract] [Full Text] [Related]
12. Vogt-Koyanagi-Harada disease after stapedotomy.
Accorinti M; Gilardi M; Nardella C; Amorelli GM; Pesci FR
Eur J Ophthalmol; 2015 Oct; 25(6):e127-30. PubMed ID: 25982211
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
14. Ocular brucellosis vs Vogt-Koyanagi-Harada syndrome.
Goldstein DA; Tessler HH
Arch Ophthalmol; 2006 Apr; 124(4):608-9; author reply 609. PubMed ID: 16606901
[No Abstract] [Full Text] [Related]
15. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
16. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
17. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.
Matsuo T; Masuda I; Ota K; Yamadori I; Sunami R; Nose S
Acta Med Okayama; 2007 Oct; 61(5):305-9. PubMed ID: 17971847
[TBL] [Abstract][Full Text] [Related]
18. Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.
Duan J; Wang Y; Liu D; Ma J
Ocul Immunol Inflamm; 2019; 27(2):229-234. PubMed ID: 29023176
[TBL] [Abstract][Full Text] [Related]
19. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
20. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
